Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(01): 20-22
DOI: 10.4103/sajc.sajc_63_19
ORIGINAL ARTICLE: GI Cancers

A prospective comparative study between concurrent chemoradiation with brachytherapy boost with concurrent chemoradiation alone in locally advanced cancer esophagus

Rajanigandha Tudu
Department of Radiotherapy, RIMS, Ranchi, Jharkhand
› Author Affiliations Financial support and sponsorship: Nill.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Context: Carcinoma esophagus is a highly malignant disease with very low cure rate. Concurrent chemoradiation is the standard of care in patients deemed unfit for surgery. Intraluminal brachytherapy (ILRT) is effective for palliation of dysphagia and is also used as a boost to external beam radiotherapy (EBRT) in curative intent. Aims: The aim of the study was to compare the clinical outcome of definitive concurrent chemoradiation followed by ILRT boost with concurrent chemoradiation alone in locally advanced carcinoma esophagus in terms of tumor response and toxicities. Settings and Design: A single institutional prospective study was carried out between January 2014 and June 2015. Subjects and Methods: Fifty-seven patients of locally advanced carcinoma esophagus were allocated to study and control arms. Both groups were treated with definitive concurrent chemoradiation with 44 Gy of EBRT. The chemotherapy consisted of injection cisplatin 70 mg/m2 intravenous on day 1 with capecitabine 800 mg/m2 b.i.d. daily from day 1 to 4 orally on days 1 and 22 of EBRT. After 2 weeks, the control group was treated with EBRT boost of 10 Gy in 5 fractions, while the study group received intraluminal high-dose rate (HDR) brachytherapy boost of 10 Gy in 2 fractions. No concurrent chemotherapy was administered during ILRT. The treatment outcome was assessed in terms of tumor response and toxicities using the CTCAE version 4.0 criteria. Results: At a median follow-up of 10 months, the overall response rate was 89.2% in the control group (25/28) and 93.10% in the study group (27/29). Acute hematological and gastrointestinal toxicities were noted. Conclusions: HDR ILRT in combination with EBRT is effective for treating dysphagia in cancer esophagus with low incidence of severe complications.

Key words

Chemoradiation - esophageal cancer - external beam radiotherapy - intraluminal brachytherapy


Publication History

Article published online:
14 December 2020

© 2020. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB Jr., Ajani JA, et al. Treatment outcomes of resected esophageal cancer. Ann Surg 2002;236:376-84.
  • 2 Sykes AJ, Burt PA, Slevin NJ, Stout R, Marrs JE. Radical radiotherapy for carcinoma of the oesophagus: An effective alternative to surgery. Radiother Oncol 1998;48:15-21.
  • 3 Gignoux M, Roussel A, Paillot B, Gillet M, Schlag P, Favre JP, et al. The value of preoperative radiotherapy in esophageal cancer: Results of a study of the E.O.R.T.C. World J Surg 1987;11:426-32.
  • 4 Lettmaier S, Strnad V. Intraluminal brachytherapy in oesophageal cancer: Defining its role and introducing the technique. J Contemp Brachytherapy 2014;6:236-41.
  • 5 Czito BG, DeNittis AS, Palta M, Willett CG. Esophageal Cancer. In: Halperin EC. editor. Perez and Bradys Principles and practice of radiation oncology. Wolter Kluwers Lippincott Williams and Willins 6th ed. 2013; p. 1019.
  • 6 Lettmaier S. Intraluminal brachytherapy in oesophageal cancer: Review paper. J Contemp Brachytherapy 2014;2:236-41.
  • 7 Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-8.
  • 8 Gaspar LE, Winter K, Kocha WI, Coia LR, Herskovic A, Graham M, et al. Aphase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): Final report. Cancer 2000;88:988-95.